This has been a whirlwind year for the clinical trials landscape. We’ve seen major shifts in federal research funding, the introduction of National Priority Vouchers, the unveiling of the plausible mechanism regulatory pathway, and rapid expansion of AI capabilities for both regulators and developers. With renewed support from the FDA and partners across the ecosystem, it has been a privilege to collaborate and convene in the midst of such meaningful change.

I’m pleased to share our Annual Report, Bridging Vision & Impact, which highlights outcomes from our 2025 meetings on the State of Clinical Trials, Balance in the Regulatory Ecosystem, and the evolving role of AI in clinical development. It also showcases how our projects are driving practical improvements in trial design and execution.

At CTTI, we are committed to adaptability and responsiveness as market, policy, and regulatory priorities evolve. Looking ahead to 2026, we see a tremendous opportunity for acceleration. As always, your leadership and engagement will be the essential enabling factors.

Thank you for being a part of CTTI. Happy Holidays!